Clinical Trials Browser

Phase 2 × Ovarian Neoplasms × Cyclophosphamide × Clear all

NCT03412877 2026-03-17

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Phase 2 Recruiting

BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT04931342 2026-03-10

BOUQUET

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT01174121 2026-03-04

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Phase 2 Recruiting

BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06083844 2026-03-04

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Phase 2 Recruiting

Ovarian Neoplasms

NCT03029403 2025-09-19

Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03610490 2025-04-17

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Phase 2 Terminated

16 enrolled 11 charts

GastrointestinalGynecologic

Ovarian Neoplasms, Colorectal Neoplasms

NCT04102436 2024-03-12

Non-Viral TCR Gene Therapy

Phase 2 Withdrawn

BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Urogenital Neoplasms

NCT02562365 2022-07-27

ACTS

Phase 2 Unknown

Ovarian Neoplasms

NCT03836352 2022-03-31

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Phase 2 Active not recruiting

GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Ovarian Neoplasms

NCT02853318 2021-10-06

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

40 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02948101 2019-03-12

PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00856180 2018-09-10

Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies

Phase 2 Completed

20 enrolled 9 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00002943 2018-08-10

Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer

Phase 2 Completed

GenitourinaryGynecologic

Testicular Germ Cell Tumor, Ovarian Neoplasms, Testicular Neoplasms

NCT00001426 2018-04-05

A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer

Phase 2 Completed

Ovarian Neoplasms

NCT00652899 2017-12-28

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Phase 2 Terminated

14 enrolled 9 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01105650 2017-12-28

MT2009-30

Phase 2 Completed

13 enrolled 11 charts

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00003852 2016-06-23

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors

Phase 2 Terminated

GenitourinaryGynecologic

Testicular Germ Cell Tumor, Ovarian Neoplasms, Testicular Neoplasms

NCT01175772 2015-06-23

Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy

Phase 2 Terminated

Carcinoma, Ovarian Neoplasms

NCT00072566 2015-05-12

Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Phase 2 Completed

70 enrolled 7 charts

Ovarian Neoplasms

NCT00025441 2013-12-04

Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors

Phase 2 Completed

GynecologicSarcoma

Malignant mesenchymal tumor, Hemangiopericytoma, Malignant, Chondrosarcoma, Fibrosarcoma, Hemangiosarcoma, Liposarcoma, Ovarian Neoplasms, Sarcoma, Neuroectodermal Tumors, Primitive, Peripheral, Desmoplastic Small Round Cell Tumor

NCT00002489 2013-06-26

Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors

Phase 2 Completed

Teratoma, Ovarian, Ovarian Neoplasms

NCT00002474 2013-05-30

Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00003386 2013-04-11

Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Phase 2 Terminated

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00844506 2011-02-25

ISA-P53-CTX

Phase 2 Completed

Ovarian Neoplasms

NCT00003269 2011-01-10

Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors

Phase 2 Completed

BreastDermatologicGynecologicLymphoidOther hematologic neoplasmThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Burkitt Lymphoma, Carcinoma, Non-Small-Cell Lung, Hodgkin Disease, Lung Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Ovarian Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Drug-Related Side Effects and Adverse Reactions